Abstract Reduction in the amount of brain-derived neurotrophic factor (BDNF) in corticostriatal afferents is thought to contribute to the vulnerability of medium spiny striatal neurons in Huntington's disease. mice. These results demonstrate that exogenous BDNF restores striatal opioid and D 3 R gene expression in mice with genetically reduced levels of endogenous BDNF.
Introduction
Medium spiny neurons (MSNs) are a specific type of GABAergic projection neuron that comprise approximately 95% of the total population of neurons in the striatum. In the caudate-putamen (CPu), MSNs can be divided into two neurochemically distinct populations that characterize different striatal projection pathways (Gerfen and Young 1988) . The striatonigral pathway projects from the striatum to the internal segment of the globus pallidus (rodent entopeduncular nucleus) and the substantia nigra; these neurons express D 1 receptors and express the opioid peptide, dynorphin, and the tachykinin, substance P. In contrast, the striatopallidal pathway projects from the striatum to the external segment of the globus pallidus. The striatopallidal pathway expresses D 2 receptors and the opioid peptide, enkephalin. In the nucleus accumbens (NAc), the expression of neuropeptides is less segregated than in the CPu; i.e., MSNs expressing dynorphin, enkephalin and substance P project to the ventral pallidum whereas MSNs expressing dynorphin and substance P project to the ventral tegmental area (Robertson and Jian 1995) . In addition, the dopamine D 3 receptor (D 3 R) is expressed more abundantly in the NAc than in the CPu (Diaz et al. 2000) . Like dopamine receptors in the CPu, the D 3 receptor has been implicated in various neuropsychiatric disorders, including schizophrenia, depression, Parkinson's disease, and drug addiction (Sokoloff et al. 2006) . The expression of D 3 R, dynorphin, and enkephalin is tightly regulated by glutamate and dopamine and by brain-derived neurotrophic factor (BDNF) in cortical and mesencephalic projections to the striatum (Sauer et al. 1994; Wang et al. 1994; Arenas et al. 1996; Wang and McGinty 1996; Guillin et al. 2001; Saylor et al. 2006) and is also increased after acute cocaine, methamphetamine, and morphine exposure (Le Foll et al. 2005; Simpson and McGinty 1995; Wang et al. 1994 Wang et al. , 1995 Wang and McGinty 1996) .
BDNF is a dynamic mediator of activity-dependent neuronal plasticity throughout the CNS (Turrigiano and Nelson 2004; Bramham and Messaoudi 2005) and is required to maintain the normal phenotype and functioning of striatal MSNs (Sauer et al. 1994; Saylor et al. 2006) . BDNF also facilitates the survival of MSNs after various types of insults, including hypoxia/ischemia (Galvin and Oorschot 2003) , oxidative stress (Petersén et al. 2001) and in experimental models of Huntington's disease (Canals et al. 2004; Pérez-Navarro et al. 2000; Alberch et al. 2002; Baquet et al. 2004; Kells et al. 2004; Zuccato et al. 2005) . Furthermore, BDNF is depleted in the striatum and/or in the cerebral cortex of Huntington's disease patients (Gauthier et al. 2004; Zuccato et al. 2001) .
Although striatal MSNs express a negligible amount of intrinsic Bdnf mRNA, the striatum receives extensive projections from glutamatergic afferents originating in cortex, hippocampus, and amygdala, as well as mesencepahlic dopaminergic afferents that synthesize BDNF and transport the protein anterogradely (Altar et al. 1997; Altar and DiStefano 1998; Conner et al. 1997; Sauer et al. 1994) . The biological effects of BDNF are primarily mediated by its protein tyrosine kinase receptor, TrkB (Ringstedt et al. 1993; Wong et al. 1997) , which is abundantly expressed throughout the dorsal and ventral striatum in the postsynaptic density (PSD) of both dynorphin-and enkephalinexpressing populations of MSNs (Freeman et al. 2003 , Guillin et al. 2001 .
Preprodynorphin (PPD) and preproenkephalin (PPE) mRNA is substantially reduced in striatal MSNs of young Bdnf ?/-mice and more global deficits in MSN gene expression, as well as the number of dendritic spines on MSNs, occur in aged Bdnf ?/-mice (Saylor et al. 2006 ). Exogenous BDNF has been infused acutely, repeatedly, or continuously into the striatum or substantia nigra to investigate whether BDNF regulates striatal gene expression in intact or lesioned animals and in mutant mouse models (Arenas et al. 1996; Guillin et al. 2001; Sauer et al. 1994) . Exogenous BDNF attenuated the decrease in the expression of D 3 receptors, and preprotachykinin mRNA, but it had no effect on increased PPE mRNA, in 6-hydroxydopamine-treated rats (Guillin et al. 2001; Sauer et al. 1994) . Further, continuous infusion of BDNF into the striatum for a week did not alter the number of DARPP-32-positive neurons, a marker of all MSNs, in Bdnf ?/-mice versus wildtype mice (Canals et al. 2004) . Taken together, these data indicate that BDNF differentially regulates gene expression in, and the integrity of, striatal MSNs. The present study was designed to determine whether infusion of exogenous BDNF into the striatum would restore the depressed striatal gene expression observed in mice with genetically reduced levels of endogenous BDNF.
Materials and methods

Animals
Bdnf ?/-and wildtype mice were generated as described previously (Liebl et al. 1997 ) and subsequently backcrossed for 10-12 generations onto a C57/BL6 genetic background (Lyons et al. 1999) . Bdnf ?/-mice carry a single null allele for BDNF and are viable, fertile, and have a normal life span, whereas mice homozygous for the mutant BDNF allele do not survive into adulthood. The mice used in this study were bred in HET 9 HET matings and genotyped locally at the Medical University of South Carolina as previously described (Saylor et al. 2006 ). Three-month-old male littermates were group-housed in a temperature and humidity controlled room and maintained on a 12 h light/dark cycle with food and water available ad libitum. All procedures used on animals in this study were in strict accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee.
Intrastriatal microinjections
Mice were anesthetized using a mixture of ketamine hydrochloride (100 mg/kg, i.p.; Fort Dodge Animal Health, Fort Dodge, IA, USA) and xylazine (10 mg/kg, i.p.; Bayer, Shawnee Mission, KS, USA). While under anesthesia, mice were mounted onto a stereotaxic device (Stoelting, Wood Dale, IL, USA), and bilateral stainless steel guide cannulae (26 gauge, Plastics One, Roanoke, VA, USA) were lowered to 2 mm above the striatal target region (AP ?0.9 mm, ML 2.0 mm, DV -3.4 mm, relative to bregma, Franklin and Paxinos 1999) . Infusion cannulae (33 gage; Plastics One) were inserted bilaterally into the guide cannulae such that 2 mm of the infusion cannulae extended past the end of the guide cannulae. Human recombinant BDNF (R & D Systems, Minneapolis, MN, USA) or sterile 10 mM phosphatebuffered saline (PBS) was infused into mice (n = 6 per group) using 10 ll Hamilton syringes and an infusion pump (Harvard Apparatus, Holliston, MA, USA). BDNF (0.75 lg/ll PBS/side) was infused over 5 min and the infusion cannulae remained in the guide cannulae for 5 min before and after the infusion. This dose of BDNF has been used previously by our laboratory (Berglind et al. 2007 (Berglind et al. , 2009 in an in vivo single injection protocol in rats. Twentyfour hours after the infusion, mice were euthanized with an overdose of Equithesin (5 ml/kg, i.p.) and the whole brain was snap-frozen in isopentane at -35°C in preparation for semi-quantitative in situ hybridization histochemistry.
Semi-quantitative in situ hybridization histochemistry
Semi-quantitative in situ hybridization histochemistry was performed as previously described (Gonzalez-Nicolini and McGinty 2002) . Briefly, sections were cut at 12 lm with a cryostat through the striatum of each mouse and thawmounted onto Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA). The sections were pretreated to fix and defat the tissue and block non-specific hybridization. Synthetic cDNA oligodeoxynucleotide probes (48-mers) complementary to PPD (NCBI GenBank Accession number NM 019374, bases 839-886), PPE (NM 017139, bases 715-762), and D 3 R (NM 007877, bases 753-800) were radiolabeled with 35 S-dATP (1,250 Ci/mmol; New England Nuclear, Boston, MA) using terminal deoxynucleotide transferase (Roche Diagnostics, Indianapolis, IN). Sections were immersed in 5.0 9 10 5 cpm/20 ll hybridization buffer/section overnight (*15 h) at 37°C in a humid environment and then washed and air dried before being placed into a film cassette with 14 C standards (American Radiolabeled Chemicals, St. Louis, MO) and Kodak Biomax film (Rochester, NY) for 4 days (PPE), 10 days (PPD), or 6 weeks (D 3 R).
Quantitation of the hybridization signals was performed using NIH image 1.62 (W. Rasband, NIMH) on a Macintosh G3 as previously described (Gonzalez-Nicolini and McGinty 2002).
14 C standards were used to generate a calibration curve. Nonuniform illumination was corrected by saving a ''blank field.'' The upper limit of the density slice option was set to eliminate film background, and this value was used to measure all images. The lower limit was set at the bottom of the LUT scale. An appropriately sized oval field encompassing the centrolateral CPu or NAc core was used to measure hybridization signals from three sections per mouse (Fig. 1 ). Changes were expressed as (1) the number of labeled pixels per unit area (area), (2) mean density of tissue in dpm/mg, and (3) integrated density (product of area 9 mean density). Integrated density more accurately depicts the area over which changes in optical density occur because mean density alone underestimates these changes (Wang et al. 1995; Zhou et al. 2004 ). The mean integrated density ± SEM in each mouse reflects the average values of three adjacent coronal sections; therefore, measurements of the hybridization signals were strongly correlated and could not be treated independently. For each gene, a mixed factor, nested repeated-measures analysis of variance was conducted on the mean integrated density values with genotype and drug treatment as independent factors, followed by planned multiple comparison tests (least squares means) when an interaction was found or to further analyze the source of main effects as previously described (Saylor et al. 2006 ).
Verification of BDNF infusion site by immunocytochemistry
One hour after BDNF microinfusion, a subset of mice (n = 2) were transcardially perfused with 4% paraformaldehyde/10 mM PBS at 4°C. The brains were removed and postfixed in a 10% sucrose/4% paraformaldehyde solution for 2 h at 4°C, and then transferred to a 20% sucrose/PBS at 4°C to incubate overnight. Using a cryostat, 40 lm frozen sections were cut serially through the striatum and collected in PBS. Consecutive sections throughout the entire extent of the striatum were collected and incubated with primary antibody (rabbit anti-BDNF, 1:100, Santa Cruz) for 20 h at 4°C on a shaker. Sections were then incubated in biotinylated goat anti-rabbit secondary antiserum (1:200, Vector Labs) for 1 h followed by avidinbiotin-peroxidase reagents (Elite Vectastain kit, Vector Labs) for 1 h at room temperature. Sections were then transferred to the VIP chromagen (Vector Labs) and allowed to develop for 1 min, after which the sections were transferred to water for 5 min to stop the reaction. The sections were mounted out of PBS onto gelatin-coated slides and coverslipped in DPX.
Results
Intrastriatal BDNF infusion
Several commercial BDNF antisera were tested; however, all were low titer and yielded disappointing results for immunohistochemistry (data not shown). Coronal sections stained with the Santa Cruz BDNF antiserum showed enough immunoreactivity to demonstrate the spread of diffusion along with the location of the injector tip in the dorsal striatum 1 h after the microinfusion (Fig. 1) . The center of the infusion was in the dorsocentral/dorsolateral CPu and the BDNF immunoreactivity was evenly spread around the tip of the cannula.
Gene expression
A characteristic pattern of PPD mRNA was detected in the CPu of wildtype mice infused with PBS in which high expression is confined to ''patches'' surrounded by low expression in the matrix, whereas PPD mRNA in the NAc had a more abundant expression pattern that is particularly robust in the shell (Gerfen and Young 1988) . Bdnf ?/-mice expressed less PPD mRNA in the CPu than wildtype mice as previously reported in a different line of Bdnf ?/-mice (Saylor et al. 2006 ) and intrastriatal BDNF infusion increased PPD gene expression in the CPu of both genotypes (Fig. 2) , Two-way ANOVA revealed significant main effects of genotype and drug treatment (F (1,17) = 42.98, P \ 0.0001; F (1,17) = 3.39, P = 0.05) for PPD expression in the CPu. Similarly, significant main effects of genotype and drug treatment (F (1,17) = 12.64, P = 0.002; F (1,17) = 16.56, P = 0.0008) were observed for PPD expression in the NAc core. Planned comparison tests revealed that in the NAc core, Bdnf ?/-mice expressed less PPD mRNA than wildtype mice. Intrastriatal BDNF infusion induced an increase of PPD mRNA in the NAc core of both wildtype and Bdnf ?/-mice. The photomicrographs in Fig. 3 illustrate the characteristic expression pattern of PPE mRNA in control mice (WT ? PBS) in which PPE mRNA was evenly and moderately expressed throughout the dorsal and ventral striatum (Gerfen and Young 1988) . Two-way ANOVA revealed a significant genotype by microinfusion interaction for PPE expression in the CPu (F (1,16) = 3.73, P = 0.05). Planned comparisons revealed that the baseline level of PPE mRNA was significantly lower in the CPu of Bdnf ?/-mice than that of PBS-infused wildtype controls (Fig. 3) . In Bdnf ?/-mice that received an intrastriatal infusion of BDNF, PPE expression was restored to wildtype levels; however, the BDNF infusion did not increase PPE mRNA in the CPu of wildtype mice. In the NAc core, no statistically significant differences in PPE mRNA levels were detected. The photomicrographs in Fig. 4 illustrate the typical expression pattern of D 3 R mRNA in the striatum of control mice (WT ? PBS), where D 3 R mRNA was largely confined to the ventral striatum, particularly robust in the olfactory tubercle (Diaz et al. 2000) . Two-way ANOVA revealed a significant main effect of microinfusion (F (1,16) = 10.48, P \ 0.005) for D3R expression in the NAc core. At baseline, Bdnf ?/-mice expressed approximately half the level of D 3 R mRNA in the NAc core as PBS-infused control wildtype mice, although this trend did not reach statistical significance (P = 0.08; Fig. 4 ). Planned comparisons revealed that, compared to the appropriate PBS-infused control, an intrastriatal infusion of BDNF tended to increase D 3 R in the NAc core of Bdnf ?/-mice, but this trend did not reach statistical significance in wildtype mice (P = 0.07).Since D 3 R mRNA is primarily contained within the ventral striatum, the CPu was not included in the analysis.
Discussion
The present report indicates that exogenously supplied BDNF is able to restore abnormal striatal gene expression caused by a genetic reduction in endogenous BDNF levels. PPD, PPE, and D 3 R mRNA were all decreased in the CPu and NAc core of Bdnf ?/-mice versus wildtype controls. In Bdnf ?/-mice, a single bilateral intrastriatal BDNF infusion was sufficient to rescue the reduced expression of PPD, PPE, and D 3 R. Intrastriatal infusion of BDNF restored the depressed expression of PPE mRNA in the CPu of Bdnf ?/-mice to wildtype levels, but did not affect PPE expression in the CPu of wildtype mice or in the NAc core of either genotype. In contrast, an intrastriatal BDNF infusion altered the expression of PPD and D 3 R in a similar manner, by increasing expression of both genes in the striatum of wildtype and Bdnf ?/-mice. These data suggest that BDNF is an important regulator of gene expression in striatal MSNs. Multiple approaches to exogenous BDNF delivery have been previously reported; most of these studies have been conducted in rats and have employed a continuous, longterm, and/or high dose delivery of BDNF, usually via osmotic mini-pump administration for a week or more (Canals et al. 2004; Kernie et al. 2000; Berhow et al. 1996) . A study by Xu and colleagues (2004) demonstrated that different patterns of BDNF infusion differentially affect the expression and phosphorylation state of TrkB. Continuous infusion over 14 days reduced the amount of full-length TrkB and decreased levels of phospho-Trks, compared to animals that received a bolus infusion of BDNF, in which there was no change in TrkB expression. Here, we show in mice that a single, small, localized BDNF infusion is sufficient to compensate for a genetic deficit that has been present throughout the development of the animal. Further, this single infusion into the dorsal striatum increased PPD and D 3 R gene expression in both CPu and NAc core 24 h later. We have demonstrated by immunocytochemistry ( Fig. 1) that microinfusion is an effective method by which to deliver BDNF and that the infused BDNF spread throughout the dorsal striatum. Although our gene expression studies were conducted in tissue processed 24 h after the microinfusion, we illustrate the extent of the BDNF infusion at 1 h because exogenous BDNF would have diffused away and been transported to other brain areas and therefore be unobservable at 24 h. Since we observed gene expression changes in both CPu and NAc core at 24 h after a local microinfusion into the dorsal striatum, it is likely either that infused BDNF spread beyond the region illustrated at 1 h in Fig. 1 to affect NAc gene expression 24 h later or that BDNF had indirect, circuit-level effects on NAc gene expression after transport from the CPu to basal ganglia structures that innervate NAc like the substantia nigra.
There are two main populations of MSNs within the striatal complex: MSNs that express D 1 R and PPD and MSNs that express D 2 R and PPE. The D 3 R is primarily co-localized in those MSNs that express the D 1 R and PPD, whereas PPE-containing MSNs do not express D 3 Rs (Curran and Watson 1995) . Our data suggest that D 1 /D 3 R and PPD-expressing neurons in the striatum are more sensitive to BDNF regulation than D 2 /PPE-expressing MSNs. It is possible that the high level of PPE gene expression in indirect pathway neurons that is regulated by adenosine A 2A and glutamate receptor stimulation requires the presence of TrkB receptors in the PSD for normal functioning, but cannot be further augmented by BDNFTrkB stimulation in wildtype mice. However, when there is a BDNF-TrkB receptor signaling deficit as in Bdnf ?/-mice, this high level of PPE gene expression is compromised, possibly by disrupting PSD signaling, that can be restored by BDNF infusion. In a transgenic mouse model of Huntington's disease, intra-striatal infusion of BDNF via osmotic mini-pump for a week restored PPE, but not preprotachykinin mRNA levels, suggesting selectivity of BDNF for the most vulnerable MSN population in Huntington's disease patients (Canals et al. 2004) .
The expression profiles of PPD and D 3 R changed similarly, and in a different and more dynamic manner than PPE expression, particularly in the NAc core, after an intrastriatal BDNF infusion. In wildtype mice, intrastriatal BDNF infusion elevated PPD and D 3 R gene expression above the levels observed in PBS-infused wildtype mice. Interestingly, intrastriatal BDNF infusion administered to Bdnf ?/-mice induced a larger increase in PPD and D 3 R mRNA expression than the increase observed in wildtype mice. That is, relative to PBS-infused controls of the same genotype, Bdnf ?/-mice showed a much greater percent increase in gene expression compared to wildtype mice that also received a BDNF infusion. For example, PPD mRNA was increased by 127% in the CPu of Bdnf ?/-mice that received a BDNF infusion, versus a 63% BDNF-induced increase observed in wildtype mice. Similarly, D 3 R mRNA was increased by 247% in the NAc core of Bdnf ?/-mice that received a BDNF infusion, versus a 92% BDNFinduced increase observed in wildtype mice. It is possible that the augmented response to exogenous BDNF observed in Bdnf ?/-mice was due to a compensatory increase in TrkB receptors in a system with genetically reduced levels of BDNF. When the availability of BDNF was increased via the microinfusion, enhanced signaling via TrkB receptors on D 3 R-and PPD-expressing neurons could result in augmented gene expression exceeding that of wildtype mice. Indeed, the fact that PPE mRNA was not altered by BDNF infusion in wildtype mice but was increased in Bdnf ?/-mice is also consistent with this interpretation (see above). Further studies are required to determine whether alterations in TrkB receptors are indeed responsible for the amplified increase in BDNF-induced gene expression in Bdnf ?/-mice. More than 70% of neurons in the NAc co-express mRNA for both TrkB and D 3 receptors (Guillin et al. 2001) . BDNF is required for normal expression of D 3 R in the NAc during development, but does not affect expression of either D 1 or D 2 receptors (Guillin et al. 2001) . BDNF from both cortical and ventral tegmental afferents directly regulates D 3 R expression in the NAc in adulthood; the typical levodopainduced increase of D 3 R expression and behavioral sensitization to repeated levodopa treatments was prevented in rats that were either decorticated or dopamine-depleted (Guillin et al. 2001 ). Further, a single injection of cocaine, methamphetamine, or morphine induces a transient increase of Bdnf mRNA in the prefrontal cortex that is followed by a long-lasting elevation of D 3 R expression in the NAc (Le Foll et al. 2005) . The results from the present study indicate that D 3 R mRNA tends to be reduced in adult Bdnf ?/-mice and can be rescued by a single infusion of BDNF. In our hands, Bdnf ?/-mice display abnormal amphetamine-induced locomotor activity and striatal D 3 R gene expression (Saylor and McGinty 2008) . Further study is needed to determine whether alterations in D 3 R expression contribute to the abnormal responses to psychostimulant administration in Bdnf ?/-mice. BDNF is co-transported with glutamate and dopamine and is released by both cortical and mesencephalic afferents. However, it is estimated that approximately 95% of total striatal BDNF protein is delivered by cortical projections (Baquet et al. 2004) , with a less significant input from other afferents. The present results indicate that exogenous BDNF restores the integrity of MSNs by increasing opioid and D 3 R gene expression in mice with genetically reduced levels of endogenous BDNF.
Since the opioid peptides and the D 3 R modulate local neurotransmission within the striatum and thereby contribute to the regulation of overall striatal output, corticostriatal BDNF is in a position to fundamentally influence neuronal activity and function within the basal ganglia circuitry.
